← Back to screener

REPLIGEN CORP RGEN

Rank #1913 · Nasdaq · $10.0B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
39.0
P/E
280.4
P/B
5.22
ROE
1.9%
Op. Margin
7.5%
Debt Ratio
45%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Weak

P/E 280.4x, P/B 5.22x. Ranks in the top 65% of the universe.

Profitability ★★☆☆☆
Average

ROE 1.9%. Ranks in the top 58% of the universe.

Safety ★★★★☆
Good

Debt ratio 45%. Ranks in the top 22% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 21.1% year over year. Ranks in the top 92% of the universe.

Safety is the relative strength · Growth is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$0.0B$-0.0B$-0.0B$0.1B-27.55
2012$0.0B$-0.0B$-0.0B$0.1B-1.415
2013$0.1B$0.0B$-0.0B$0.1B17.845
2014$0.1B$0.0B$0.0B$0.1B17.880
2015$0.1B$0.0B$0.0B$0.1B33.653
2016$0.1B$0.0B$0.0B$0.1B16.874
2017$0.1B$0.0B$0.0B$0.1B16.5159
2018$0.1B$0.0B$0.0B$0.1B15.3124
2019$0.1B$0.0B$0.0B$0.2B9.994
2020$0.2B$0.0B$0.0B$0.6B13.458
2021$0.3B$0.0B$0.0B$0.6B13.461
2022$0.4B$0.1B$0.1B$1.1B19.157
2023$0.7B$0.2B$0.1B$1.5B24.940
2024$0.8B$0.2B$0.2B$1.8B28.050
2025$0.6B$0.0B$0.0B$1.9B7.545

← See the full screener